FDA sees potential in this blood cancer treatment

Today’s big movers inside                                                                                                                                                                                                                                                                                                                                                                                                                 March 15, 2024 FDA sees potential in this blood cancer treatment Today’s big movers inside *Promoted by Sideways Frequency Good day, 360! Here are our top investing ideas today. These setups look primed! Be the best prepared trader on the Street! FOCUS LIST🔎 GERN - Up over 90% in pre after blood disorder drug gets FDA advisers' backing CDLX - Up over 40% in pre after much improved earnings  RLX - Up over 13% in the pre-market after earnings beat SPOTLIGHT💡 *Promoted by Sideways Frequency Hey 360! To wrap up our week, we have found another extremely interesting idea – AND it’s less than 50 cents right now. Pull up Cybin (CYBN) right now and look at it closely. CYBN is a leader in developing psychedelics-based therapies for mental illnesses including major depressive disorder (MDD), generalized anxiety disorder (GAD) and alcohol use disorder (AUD). The company came on our radar a couple of weeks ago when it was making a perfect Gamma Trigger breakout. Here’s that signal right before it snapped off a 70% move to the upside: We’ve been watching this one really closely and waiting for what could be the next spot to get involved. TODAY could be the perfect time to get CYBN on your radar. If you can see in the chart, after a pullback for a few days, CYBN is within a hair of trading back above the 20-hour line. The purple candles are signaling a potential trend change is around the corner. If that happens and they switch to blue, we could get a “GO” signal today. You know what that means… we would have another Gamma Trigger signal! So keep a close eye on CYBN today. As always, do your own due diligence. Never trade with more than you can afford to lose, and always have a well-thought-out game plan that takes your personal risk tolerance into consideration. 👊  Text “RAGE” to 1-(888) 404-5747 to get all of our latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. HOTLIST🔥 GERN - Up over 90% in pre after blood disorder drug gets FDA advisers' backing Geron Corporation (GERN) is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, Imetelstat, to treat hematologic malignancies. In the after-hours yesterday, the [company announced](: “that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to 2 in favor of the clinical benefit/risk profile of Imetelstat for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs).” GERN plans to commercially launch imetelstat in the U.S. upon potential FDA approval. This benefits of the potential blood cancer treatment confirmed by the FDA sent GERN up over 70% in the pre-market. The $3 area has acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $3.20, $3.40 and then the pre-market high at $3.71. Beyond that, $3.80, $4, $4.50 and $5 come into play. Below $3, targets to the downside are $2.70, $2.40, $2.20, $2 and a gap to fill at $1.75. CDLX - Up over 40% in pre after much improved earnings   Cardlytics, Inc. (CDLX) operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel. In the after-hours yesterday, [the company reported]( Q4 revenue of $89.2 million up 8.1% year-over year. Q4 adjusted EBITDA: Improved to $10.0 million in Q4 2023vs negative $6.1 million in Q4 2022. Q4 Net Loss decreased to -$100.8 million in Q4 2023, or -$2.56 per diluted share, from -$378.3 million, or -$11.32 per diluted share in Q4 2022. The stock traded up over 40% in the pre-market after the earnings report yesterday. $12 was resistance in the after-hours and now becomes a potential support level. Above it, the first target for bulls is the pre-market high at $12.60. Beyond that $13, $14 and $15 come into play. Below $12, targets to the downside are $11.50, $11, $10.83, $10, $9.50, $9 and a gap fill at $8.19. RLX - Up over 13% in the pre-market after earnings beat RLX Technology Inc. (RLX) together with its subsidiaries, engages in the manufacture and sale of e-vapor products in the People's Republic of China. It serves partner distributors and retail outlets. This morning, the [company announced]( Q4 net revenues of RMB520.5 million (US$73.3 million) vs RMB340.0 million in the same period of 2022. U.S. GAAP net income was RMB216.0 million (US$30.4 million) in Q4 vs U.S. GAAP net loss of RMB225.1 million in the same period of 2022. The stock traded up over 13% in the pre-market after the earnings releases. The $2.02 area has acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $2.18 and then the pre-market high at $2.24. Beyond that, targets to the upside are $2.50 , $3 and $3.50. Below $2.02, targets to the downside are a gap fill to $1.95 and then $1.85. MARKET NEWS 📰 Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLOSURES *PAID ADVERTISEMENT. Raging Bull has currently been paid twenty thousand dollars from Sideways Frequency, who was compensated by a third party not affiliated with the Company for advertising Cybin Inc for a one-day marketing program commencing on march 15, 2024. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Cybin Inc, increased trading volume, and possibly an increased share price of Cybin Inc’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in Cybin Inc, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States of America